Introduction
In 1879 William Gowers, the eminent British neurologist, painted a remarkably lucid word picture of Duchenne muscular dystrophy in his series of lectures on pseudohypertrophic muscular paralysis, published in the Lancet.' This disease, he said, is one of the most interesting, and at the same time most sad, of all those with which we have to deal; interesting because of its peculiar features and mysterious nature; sad on account of our powerlessness to influence its course.
Almost exactly a century later Duchenne dystrophy found itself at the centre of one of the most exciting breakthroughs in the modern science of molecular genetics. It was the first genetic disorder in which a previously unknown biochemical abnormality was resolved by the process of reversed genetics, with initial location, isolation and cloning of the gene and then identifying the protein it encodes. Moreover, we now seem to be on the verge of treating the disease by one or other of the potential routes of gene therapy. This would certainly have delighted Gowers. At the same time molecular genetics has generated a most complex and almost totally incomprehensible new jargon of its own, which must surely have turned Gowers in his grave.
The muscular dystrophies, a term first coined by Erb in 1891, are a group of genetically determined disorders characterized by degeneration of skeletal muscle and no associated structural abnormality in the central or peripheral nervous system. They have been subdivided into various clinical types on the basis of the clinical distribution and severity of muscle weakness, and the mode of inheritance. The rate of progression of the disease is also variable and some, such as congenital muscular dystrophy, may remain relatively static or even show functional improvement over time. Some of the animal models of the dystrophies may be devoid of any clinical weakness as may some of the milder variants of, for example, Becker dystrophy, which can present solely with cramps on exercise.1 '2 The main breakthrough has been in Duchenne and Becker muscular dystrophy, or the Xp2l dystrophies as some would now have us call them. The location of the gene for the X-linked Emery-Dreifuss muscular dystrophy on the long arm of the X chromosome at Xq28 was discovered a few years back3 but there has as yet been no further progress in its resolution. The locus for the dominantly inherited facioscapulohumeral dystrophy on the long arm of chromosome 4 Similarly in Becker muscular dystrophy the suggestion of altered size or molecular weight of dystrophin excluded the possibility of a normal-sized protein of reduced amount.
The application of immunocytochemical techniques to the study of dystrophin in muscle sections added a new dimension to the interpretation. In contrast to the early suggestion based on the biochemical fractionation studies that dystrophin might be localized to the triads, the cytochemical studies showed a clear-cut localization to the sarcolemmal membrane.14"15
While confirming the general absence of any staining for dystrophin in Duchenne biopsies, it has also consistently revealed small numbers, usually less than 1%, of positive staining fibres in some Duchenne biopsies. It has been suggested that these may represent a somatic mutation, with reversion to normal, in individual fibres. In Becker biopsies there may be a variation in the intensity of stain in the positive fibres and also the presence of patchy rather than continuous staining of the membrane in individual fibres. In female carriers the results are also interesting, but somewhat complex. Although manifesting carriers may show a mosaic pattern of positive and negative fibres,'6 the majority of non-manifesting carriers that we have reviewed have shown an essentially normal dystrophin pattern with practically all fibres showing a normal staining pattern. '7 In addition to the original Hoffman antibodies, a number oflaboratories have produced antibodies to different parts of the dystrophin molecule which has allowed a more comprehensive appraisal of the changes in dystrophin in the muscle in parallel with the deletion studies in the gene. Nicholson et al. '6 recently reported their experience in a comparative study of immunoblotting and immunocytochemistry in a large series of 226 muscle biopsies, including 85 Duchenne and 55 Becker dystrophies, using a monoclonal antibody to the rod domain of dystrophin, which was specific for dystrophin and did not crossreact with spectrin or alpha-actinin. They found isolated positive fibres in 40% of the Duchenne biopsies and a further 20% had weak labelling of a large number of fibres. Of the 54 Duchenne and 52 Becker biopsies showing a positive band on immunolabelling, 85% had a protein of abnormal size, whereas the remaining 15% had a protein of normal size but reduced abundance. They found that overall there was a good correlation between the abundance of dystrophin and clinical severity.
A lot more cumulative experience is still required comparing the severity of the clinical disease with the deletion data in relation to the gene and the changes in the dystrophin in the muscle. Meanwhile it would be prudent (for biochemists as well as physicians) not to lose sight of the importance of careful clinical assessment of the patient in relation both to the extent of weakness and the rate of progression of the disease, rather than trying to predict these from the laboratory data in isolation.
Animal models of X-linked (Xp2l) dystrophies
A number of animal models of the Xp2l dystrophy have been identified in recent years and have already attracted a lot of research interest both from the investigative and from the therapeutic point of view.
The mdx mouse
An X-linked dystrophy in the mouse was picked up purely by chance during a mutagenesis screen of serum enzymes.'8 Following a period of necrosis of the muscle at about 2-3 weeks of age there is active regeneration and recovery and the mice then remain essentially normal and have a normal lifespan.'9 The gene for the mouse dystrophy is homologous to the human dystrophin gene,20 and dystrophin is also absent in the mdx mouse muscle.9 It has recently been shown that the genetic abnormality is a point mutation at nucleotide position 3185, with the replacement of the nucleotide cytosine by a thymine, resulting in a termination codon (TAA) in place of a glutamine codon (CAA The exact genetic mutation has not yet been identified, but no deletions have been found. As in the case of the mdx mouse, all the descendants within the same strain will presumably have the same mutation. Cooper has recently diagnosed a dystrophin-deficient dystrophy in a pair of sibling male Rottweiler pups, aged 5 months.25 Clinically they were more severely affected than the previous Retriever progeny. The canine X-linked muscular dystrophy is thus likely to affect many different strains of dog, and a number of case reports of myopathies in dogs in the earlier veterinary literature may well have been cases of abnormalities in the dystrophin gene.
The XMD cat A dystrophin-deficient muscular dystrophy has been documented in a single neutered male cat, which was not clinically weak and had marked prominence of the muscles. 26 Cooper has recently investigated a similar male cat with a dystrophindeficient dystrophy, which had a remarkable degree of muscular hypertrophy and no obvious clinical weakness. This feline model of muscular dystrophy is of special interest in parallel with the mouse dystrophy for its absence of clinical weakness and its marked muscle hypertrophy, which probably also occurs in the mdx mouse, and is, ofcourse, also a feature of selected muscles in the human disease, the so-called pseudohypertrophy already noted by Duchenne, who coined the term.
Therapeutic possibilities

Gene therapy
The dramatic advances in the past few years in relation to the dystrophy gene naturally raised the hopes of sufferers and their families that a cure might be around the corner. It also sparked speculation in the scientific community on the possibility of gene therapy. Techniques already exist for the introduction of DNA into somatic or germline cells, either directly or with viral or other vectors. One major hurdle was the tremendous size of the gene which would be beyond the capacity of retroviral vectors. Possible ways around this were the use of alternative vectors such as yeast artificial chromosomes or the construction of a 'mini' gene from the DNA of a patient with mild Becker type dystrophy and the deletion of about half of the dystrophin, yet still capable of producing a functional protein about half the normal size.27
Moreover it has recently been shown that DNA injected directly into muscle remains functionally viable, thus bypassing the need for a vector. 28 To crown it all, Caskey's laboratory have just succeeded in producing a construct of the whole dystrophin gene, and shown that the recombinant dystrophin that it produced was indistinguishable from mouse muscle dystrophin by Western blot analysis with anti-dystrophin antibodies, and was localized to the cell membrane with fluorescent antibody techniques.29 This adds further credence and hope to the possibilities of direct gene therapy, but there are still major hurdles to be overcome such as the targeting of the replacement gene to the affected muscles.
Myoblast transfer
An attractive, feasible and potentially practical short cut, which could provide an alternative approach to the replacement of either the gene or its protein product, has been the introduction of normal muscle cells, in the form ofactively dividing cultured myoblasts, directly into the dystrophic muscle. These myoblasts can then fuse with the regenerating mononucleate satellite cells of the host, which lie dormant under the sarcolemmal membrane of normal as well as dystrophic muscle, until activated. The multinucleate muscle cells formed are thus a combination of normal and dystrophic cells, comparable to the female carrier of the Duchenne gene, and hopefully sufficiently functional to provide reasonable muscle power.
Earlier experimental work in mice showed the fusion of donor and host myoblasts to produce hybrid multinucleate muscle cells,30 and to introduce genes from the donor cells.3' This approach was subsequently used by Law and his colleagues32 to try to correct the abnormality in the autosomal recessive muscular dystrophy in the mouse. In a recent application of the technique in the mdx mouse, Partridge and his colleagues demonstrated the fusion of normal donor muscle cells with the muscle cells of the host with the production of hybrid multinucleate fibres. These fibres were also capable of expressing dystrophin, which was consistently absent in the host muscle. 33 While the mdx mouse is a good model for establishing the experimental aspects of this therapeutic approach, and has the advantage of the small muscle size in relation to the number of injected cells, it is not a good model for assessing potential clinical benefit in the absence of any clinical weakness. In this respect the XMD dog, with its clinical phenotype and pathological picture more closely resembling Duchenne dystrophy, should provide a better model.
Human myoblast transfer experiments
Fired by the apparent success of the technique in the mdx mouse, a number of centres in North America opted to plunge forthwith into experiments in patients with Duchenne dystrophy to evaluate the potential therapeutic value in the context of the human disease. They anticipated that they would be able to resolve such basic questions as the minimum and optimal number of cells needed to be effective, the method ofintroduction and dispersion of the cells into the host muscle, and the short-term or long-term need for immunosuppression, as part of the experimental design. As in any therapeutic trial, it is absolutely essential to have objective and reliable methods to assess the outcome of the experiment, both from the point of view of the successful fusion of the donor with the host cells and the expression of dystrophin in a previously dystrophin-negative subject, and also the effect this has on the pathological state of the muscle, and its clinical function.
From an immunological compatibility point of view, the ideal donor would probably be a sibling, but in view of the ethical constraints on using minors in the context of such experiments, the father has usually been chosen.
Karpati and his team in Montreal, Canada, are injecting cultured myoblasts from the father into the biceps muscle of boys with proven Duchenne dystrophy and an associated deletion in the dystrophin gene. This is done randomly and blindly, the other biceps having a comparable injection without the myoblasts in. The presence of dystrophin in the injected muscles on both sides is being assessed after 3 months in open biopsy samples with both Western blotting and immunocytochemical techniques. The muscle strength in the elbow flexors is also being measured sequentially.
Law and his colleagues in Memphis, USA, are conducting a similar series of experiments on the extensor digitorum brevis muscle on the dorsum of the foot, using cultured myoblasts from the father, and comparing the results with the sham-injected opposite side. The small size of the muscle has potential advantages in relation to the number of cells needed for the procedure, but limitations if more than one biopsy were envisaged or in accurate measurement ofmuscle force. These studies are still very much in the experimental stage. It will not be feasible to proceed to the next phase of actual therapeutic trials of myoblast transfer in appropriate patients to assess the potential impact on the disease itself until we have a clear-cut and unequivocal answer to the basic question as to whether the technique produces significant and adequate expression of dystrophin in the host muscle, and what beneficial effect this has on the muscle pathology and particularly on the clinical function. It is also imperative for the wide publicity that this work has already had in the lay press to be toned down in order to avoid unwarranted hope in the sufferers and their families together with the frustration of thinking (misguidedly) that they are already missing out on actual beneficial treatment by not being where the action lies.
Meanwhile, we may be able to get a further appraisal of the therapeutic potential ofthis technique in the dystrophic dog, and I have established a collaborative programme with Dr Barry Cooper's group at the New York State College of Veterinary Medicine at Cornell University in Ithaca, USA. There are a number of advantages in the dog model. One can use siblings as donors and carefully control the timing ofthe injections in relation to the stage of the pathological process and also compare different muscles which may be at different stages in the same animal. There are also major hurdles to be overcome in the canine model such as the difficulty in culturing cloned myoblasts in quantity with existing culture media which may be optimal for human or mouse muscle, and the relatively rudimentary status of knowledge in relation to the dog's immunological systems, compared to man or mouse.
Conclusions
The muscular dystrophies are currently at a very exciting stage of active resolution of many of the fundamental questions that have puzzled and eluded clinicians and scientists for the past century. The Duchenne gene has been cloned, its protein identified and its location accurately mapped to the inner surface of the sarcolemmal membrane. Its function has not yet been fully established but it is thought to have a stabilizing role in the integrity of the membrane in close association with linked glycoproteins. The absence or abnormality of dystrophin presumably triggers the process of progressive degeneration and disintegration of the muscle cell, but the other factors, such as the influx of calcium, which have an important role in perpetuating the process still await more detailed study and clarification.
The new era of potential treatment of the remorselessly progressive and disabling Duchenne form of muscular dystrophy is just beginning, and things look set fair for its success, given the remarkable technical advances we have witnessed in relation to gene manipulation in the last few years.
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